1,3-thiazol-2-yl substituted benzamides
AssigneeBayer Aktiengesellschaft
InventorsAdam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
Life of this patent
Estimating the term…
Abstract
The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
Claims16
A compound of formula (I):
- wherein:
- R1 is C1-C4-alkyl;
- R2 is unsubstituted tetrahydrofuran-3-yl;
- R3 is C1-C4-alkyl;
- and
- A is CF3-pyrimidinyl;
- or an enantiomer, diastereomer, racemate, hydrate, solvate, or salt thereof, or a mixture of the foregoing.
A compound or a salt thereof, wherein the compound is 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3R)-tetrahydrofuran-3-yloxy]-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl] ethyl}benzamide.
Dependencies are inferred from the claim text.